MapLight Therapeutics, Inc. (MPLT) Earnings History
Net Loss4 years of earnings data (2022–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
MapLight Therapeutics, Inc. (MPLT) Earnings Overview
As of June 29, 2026, MapLight Therapeutics, Inc. (MPLT) reported trailing twelve-month net income of -$199M, reflecting -95.7% year-over-year growth. The company earned $-4.41 per diluted share over the past four quarters.
Looking at the long-term picture, MPLT's historical earnings data spans multiple years. The company achieved its highest annual net income of -$30M in fiscal 2022.
MapLight Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ACNB ($51M net income, 21.7% margin), PTGX (-$115M net income, -282.8% margin), TERN (-$96M net income), MPLT has comparable earnings metrics. Compare MPLT vs ACNB →
MPLT Earnings vs Peers
Earnings metrics vs comparable public companies
MPLT Historical Earnings Data (2022–2025)
4 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$161M | -107.7% | -$169M | $-3.66 | - | - |
| 2024 | -$78M | -39.3% | -$83M | $-1.87 | - | - |
| 2023 | -$56M | -85.6% | -$57M | $-1.34 | - | - |
| 2022 | -$30M | - | -$31M | $-0.72 | - | - |
Download Data
Export MPLT earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
4+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
MPLT — Frequently Asked Questions
Quick answers to the most common questions about buying MPLT stock.
What is MPLT earnings per share (EPS)?
MPLT trailing twelve-month (TTM) diluted EPS is $-4.41, reflecting -95.7% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2022 to 2025 is available in the table on this page.
What is MapLight Therapeutics, Inc.'s net income?
MapLight Therapeutics, Inc. (MPLT) trailing twelve-month net income is $-199M as of 2025. Earnings declined -95.7% year-over-year.
Is MPLT profitable?
MPLT is not currently profitable on a TTM basis, reporting a net loss of $-199M. Net margin is N/A. Investors should monitor for a return to profitability.
What is MPLT's earnings growth rate?
MPLT compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2022 to 2025.
What are MPLT's profit margins?
MapLight Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -56.2%.
Is MPLT growing earnings?
MPLT earnings are declining — EPS fell -95.7% year-over-year. TTM net income dropped to $-199M. This contrasts with the 5-year CAGR of N/A.
What was MPLT's best earnings year?
MapLight Therapeutics, Inc.'s highest annual net income on record is $-30M, achieved in fiscal year 2022. Earnings history on this page spans 2022 to 2025 and includes all annual and quarterly figures.
What were MPLT's earnings last quarter?
MPLT's most recent reported quarter was Q1 2026. Net income was $-61M with diluted EPS of $-1.34. For a full breakdown of all quarters, see the quarterly earnings table on this page.